3B BlackBio Dx Ltd — Important, 29-05-2026: Company Update

3B BlackBio Dx Limited reported strong financial results for FY 2025-26, with consolidated revenue reaching ₹141.92 Cr, up from ₹96.47 Cr last year, and profit after tax growing to ₹59.93 Cr from ₹47.69 Cr. This includes ₹35.91 Cr from the acquired Coris BioConcept SRL, Belgium. The Molecular Diagnostics (MDx) division, holding a 15% market share, projects 15-20% growth for FY 2026-27, driven by product development, global expansion, and long-term contracts. Agrochemicals maintained stable sales, despite a 22% export dip due to geopolitical tensions. The company continues to pursue strategic M&A opportunities globally.